PT  - JOURNAL ARTICLE
AU  - Boloko, Linda
AU  - Lifson, Aimee
AU  - Little, Francesca
AU  - De Wet, Timothy
AU  - Papavarnavas, Nectarios
AU  - Marais, Gert
AU  - Hsiao, Nei-yuan
AU  - Rosslee, Michael-John
AU  - Doolabh, Deelan
AU  - Iranzadeh, Arash
AU  - Williamson, Carolyn
AU  - Dlamini, Sipho
AU  - Mendelson, Marc
AU  - Ntusi, Ntobeko
AU  - Wilkinson, Robert J.
AU  - Hussey, Hannah
AU  - Davies, Mary-Ann
AU  - Meintjes, Graeme
AU  - Wasserman, Sean
TI  - Severity and inpatient mortality of COVID-19 pneumonia from Beta variant infection: a clinical cohort study in Cape Town, South Africa
AID  - 10.1101/2021.11.04.21265916
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.11.04.21265916
4099  - http://medrxiv.org/content/early/2021/11/04/2021.11.04.21265916.short
4100  - http://medrxiv.org/content/early/2021/11/04/2021.11.04.21265916.full
AB  - Background The SARS-CoV-2 Beta variant, associated with immune escape and higher transmissibility, drove a more severe second COVID-19 wave in South Africa. Individual patient level characteristics and outcomes with the Beta variant are not well characterized.Methods We performed a retrospective cohort study comparing disease severity and inpatient mortality of COVID-19 pneumonia between the first and second wave periods at a referral hospital in Cape Town, South Africa. Beta variant infection was confirmed by genomic sequencing. Outcomes were analyzed with logistic regression and accelerated failure time models.Results 1,182 patients were included: 571 during the first wave period and 611 from the second wave. Beta variant accounted for 97% of infections in the second wave. There was no difference in crude in-hospital mortality between wave periods (first wave 22.2%, second wave 22.1%; p = 0.9). Time to death was decreased with higher weekly hospital admissions (16%; 95% CI, 8 to 24 for every 50-patient increase), age (18%; 95% CI, 12 to 24 for every 10-year increase) and hypertension (31%; 95% CI, 12 to 46). Corticosteroid use delayed time to death by 2-fold (95% CI, 1.5 to 3.0). Admission during the second wave decreased time to death after adjustment for other predictors, but this did not reach statistical significance (24%; 95% CI, 47 to -2). There was no effect of HIV on survival.Conclusions There was a trend towards earlier mortality during the second COVID-19 wave driven by the Beta variant, suggesting a possible biological basis. Use of oral prednisone was strongly protective.Key points In Cape Town, South Africa, the second wave of COVID-19, dominated by the Beta variant, was associated with decreased time to inpatient death after adjustment for age, comorbidities, steroid use, and admission numbers. Use of oral prednisone was strongly protective.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Wellcome (203135/Z/16/Z) and (222574)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of the University of Cape Town Faculty of Health Sciences gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors